MX2021007402A - Metodos para la toma de imagenes y el tratamiento de tumores positivos para el receptor de somatostatina. - Google Patents

Metodos para la toma de imagenes y el tratamiento de tumores positivos para el receptor de somatostatina.

Info

Publication number
MX2021007402A
MX2021007402A MX2021007402A MX2021007402A MX2021007402A MX 2021007402 A MX2021007402 A MX 2021007402A MX 2021007402 A MX2021007402 A MX 2021007402A MX 2021007402 A MX2021007402 A MX 2021007402A MX 2021007402 A MX2021007402 A MX 2021007402A
Authority
MX
Mexico
Prior art keywords
somatostatin
methods
imaging
hkgrm
enhancing
Prior art date
Application number
MX2021007402A
Other languages
English (en)
Inventor
Andreas G Moraitis
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of MX2021007402A publication Critical patent/MX2021007402A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se dan a conocer métodos para el tratamiento, la identificación y la localización de los tumores que expresan los receptores de somatostatina (SR, por sus siglas en inglés), los cuales incluyen los métodos para mejorar la eficacia de las técnicas de toma de imágenes por medio de la administración de un modulador del receptor de glucocorticoides de azadecalina fusionada con heteroaril-cetona (HKGRM, por sus siglas en inglés) eficaz para aumentar la expresión de los SR en los tumores. La administración del HKGRM para potenciar la toma de imágenes de los tumores basados en los SR, y para el tratamiento de los tumores neuroendocrinos. una terapia de combinación de un HKGRM y somatostatina o un análogo de somatostatina para el tratamiento y la mejora de la toma de imágenes de los tumores basados en los SR.
MX2021007402A 2018-12-20 2019-12-19 Metodos para la toma de imagenes y el tratamiento de tumores positivos para el receptor de somatostatina. MX2021007402A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862783015P 2018-12-20 2018-12-20
PCT/US2019/067341 WO2020132171A1 (en) 2018-12-20 2019-12-19 Methods for imaging and treatment of somatostatin-receptor positive tumors

Publications (1)

Publication Number Publication Date
MX2021007402A true MX2021007402A (es) 2021-07-15

Family

ID=71101898

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007402A MX2021007402A (es) 2018-12-20 2019-12-19 Metodos para la toma de imagenes y el tratamiento de tumores positivos para el receptor de somatostatina.

Country Status (11)

Country Link
US (1) US20220062386A1 (es)
EP (1) EP3897629A4 (es)
JP (1) JP7444889B2 (es)
KR (1) KR20210107004A (es)
CN (1) CN113194944A (es)
AU (1) AU2019405771A1 (es)
CA (1) CA3122581A1 (es)
IL (1) IL284237A (es)
MX (1) MX2021007402A (es)
SG (1) SG11202105746TA (es)
WO (1) WO2020132171A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024054785A2 (en) * 2022-09-06 2024-03-14 Corcept Therapeutics Incorporated Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to selective glucocorticoid receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2665338T3 (es) 2012-05-25 2018-04-25 Corcept Therapeutics, Inc. Moduladores del receptor de glucocorticoides de azadecalina condensada con heteroaril-cetona
US8859774B2 (en) * 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
AU2016226451B2 (en) * 2015-03-02 2019-12-19 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat ACTH-secreting tumors
CA2989266A1 (en) * 2015-06-25 2016-12-29 Advanced Accelerator Applications Method of treatment of neuroendocrine tumors that over-express somatostatatin receptors
EP3592358A4 (en) 2017-03-09 2020-12-16 Corcept Therapeutics, Inc. USE OF GLUCOCORTICOID RECEPTOR MODULATORS IN THE TREATMENT OF CATECHOLAMIN SECRETING TUMORS
EP3876936A4 (en) * 2018-11-09 2022-08-17 Corcept Therapeutics Incorporated PROCEDURE FOR SHRINKING PITITUNITIAL TUMORS

Also Published As

Publication number Publication date
SG11202105746TA (en) 2021-07-29
JP7444889B2 (ja) 2024-03-06
JP2022515233A (ja) 2022-02-17
WO2020132171A1 (en) 2020-06-25
EP3897629A4 (en) 2022-12-07
US20220062386A1 (en) 2022-03-03
EP3897629A1 (en) 2021-10-27
IL284237A (en) 2021-08-31
AU2019405771A1 (en) 2021-06-17
CN113194944A (zh) 2021-07-30
CA3122581A1 (en) 2020-06-25
KR20210107004A (ko) 2021-08-31

Similar Documents

Publication Publication Date Title
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
PH12020551160A1 (en) Chimeric antigen receptors targeting cd70
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
EP4286008A3 (en) Method of treatment of neuroendocrine tumors that over-express somatostatatin receptors
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
EP4085967C0 (en) APPLICATION OF TUMOR TREATMENT FIELDS (CHAMPSTT) VIA ELECTRODES EMBEDDED IN CRANIAL IMPLANTS
EP4324460A3 (en) Sodium bicarbonate for use in the treatment of gout and related disorders
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
SG10201902664RA (en) Combination therapy for treating cancer
EA201790404A1 (ru) Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака
MX2022008868A (es) Tratamiento del cancer con tg02.
MX2019011543A (es) Moduladores del receptor de glucocorticoides para el tratamiento de cancer cervical.
MX2019006331A (es) Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos.
WO2015200828A8 (en) Conjugates for immunotherapy
NZ754865A (en) Combination therapy for the treatment of cancer
BR112018010536A2 (pt) dispositivo de estimulação muscular elétrica transcutânea para tratamento da ejaculação precoce ou disfunção erétil e metódos de uso respectivos
PH12015502260A1 (en) C. novyi for the treatment of solid tumors in humans
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MX2018015172A (es) Metodos para tratar cancer pancreatico.
MX2020007130A (es) Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl.
IL279591A (en) Cancer treatment methods using combination therapy
IL281439A (en) Combined treatment for blood cancer
MX2021007402A (es) Metodos para la toma de imagenes y el tratamiento de tumores positivos para el receptor de somatostatina.
MX2021003262A (es) Metodos de tratamiento.
IL281281A (en) Combined treatment for prostate cancer